From: Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients
Characteristic | Echinocandin | Fluconazole | P |
---|---|---|---|
(n = 315) | (n = 374) | ||
Male | 168 (53%) | 198 (53%) | .94 |
Age | 58 ± 17 | 56 ± 21 | .17 |
Immunosuppressive therapy within 30Â days | 189 (60%) | 155 (41%) | <.001 |
 Corticosteroids | 184 (58%) | 153 (41%) | <.001 |
Nonsteroid immunosuppressive therapy | 43 (14%) | 25 (7%) | .003 |
Renal injury (serum creatinine > 2 mg/dL or dialysis) | 146 (46%) | 124 (33%) | <.001 |
 Dialysis (chronic or acute) | 101 (32%) | 77 (21%) | <.001 |
Any malignancy | 49 (16%) | 61 (16%) | .83 |
 Hematologic malignancy | 17 (5%) | 8 (2%) | .025 |
 Solid tumor | 34 (11%) | 55 (15%) | .14 |
Neutropenia within in the preceding 30Â days | 20 (6%) | 2 (1%) | <.001 |
Diabetes mellitus | 139 (44%) | 134 (36%) | .029 |
Abnormal hepatic function | 123 (39%) | 120 (32%) | .066 |
 Transaminitis | 84 (27%) | 81 (22%) | .13 |
 Hyperbilirubinemia | 87 (28%) | 79 (21%) | .050 |
Solid organ transplant | 31 (10%) | 16 (4%) | .004 |
HIV seropositive | 6 (2%) | 5 (1%) | .56 |
Surgical patient | 119 (38%) | 164 (44%) | .12 |